| 2020 |
Bolland MJ, House ME, Horne AM, Pinel V, Gamble GD, Grey A, Reid IR. Nitrates do not affect bone density or bone turnover in postmenopausal women: a randomized controlled trial. J Bone Miner Res. June 2020;35(6):1040-1047. |
0 |
0 |
| 2021 |
Reid IR, Horne AM, Mihov B, Stewart A, Bolland MJ, Bastin S, Gamble GD. Predictors of fracture in older women with osteopenic hip bone mineral density treated with zoledronate. J Bone Miner Res. January 2021;36(1):61-66. |
0 |
0 |
| 2022 |
Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR. Bone mineral density and bone turnover 10 years after a single 5 mg dose or two 5-yearly lower doses of zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial. J Bone Miner Res. January 2022;37(1):3-11. |
1 |
0 |
| 2022 |
Reid IR, Bastin S, Horne AM, Mihov B, Gamble GD, Bolland MJ. Zoledronate reduces height loss independently of vertebral fracture occurrence in a randomized trial in osteopenic older women. J Bone Miner Res. November 2022;37(11):2149-2155. |
0 |
0 |
| 2010 |
Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. March 2010;95(3):1174-1181. |
22 |
21 |
| 2018 |
Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture prevention with zoledronate in older women with osteopenia. NEJM. December 20, 2018;379(25):2407-2416. |
45 |
36 |